The computational prediction of genotoxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 7, 2010, Pages 797-807

  Naven, Russell T ^a   Louise May, Shirley ^a   Greene, Nigel ^a  

^a PFIZER INC   (United States)

Author keywords

ACD Tox; Chromosome damage; Computational toxicology; Derek for Windows; Mutagenicity; QSAR; SAR

Indexed keywords

AMES TEST; CARCINOGENICITY; CHROMOSOME DAMAGE; COMPUTER MODEL; DRUG INDUSTRY; GENOTOXICITY; IN VITRO STUDY; MUTAGENICITY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHROMOSOME ABERRATIONS; COMPUTATIONAL BIOLOGY; DNA DAMAGE; FORECASTING; HUMANS; MUTAGENICITY TESTS; MUTAGENS;

EID: 77953941900     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.495118     Document Type: Review

References (53)

1. Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 2005;584(1-2):1-256
2. Bolt HM, Foth H, Hengstler JG, Degen GH. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Toxicol Lett 2004;151(1):29-41
3. Dragos H, Gilles M, Alexandre V. Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. J Chem Inf Model 2009;49(7):1762-1776
4. Weaver S, Gleeson MP. The importance of the domain of applicability in QSAR modeling. J Mol Graph Model 2008;26(8):1315-1326
5. Zhang QY, Aires-de-Sousa J. Random forest prediction of mutagenicity from empirical physicochemical descriptors. J Chem Inf Model 2007;47(1):1-8
6. Kazius J, McGuire R, Bursi R. Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem 2005;48(1):312-320
7. Hansen K, Mika S, Schroeter T, et al. Benchmark data set for in silico prediction of Ames mutagenicity. J Chem Inf Model 2009;49(9):2077-2081
8. Benigni R, Bossa C. Predictivity of QSAR. J Chem Inf Model 2008;48(5):971-980
9. Johnson SR. The trouble with QSAR (or how I learned to stop worrying and embrace fallacy). J Chem Inf Model 2008;48(1):25-26
10. Helma C. Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity. Mol Divers 2006;10(2):147-158
11. Matthews EJ, Kruhlak NL, Cimino MC, et al. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul Toxicol Pharmacol 2006;44(2):97-110
12. Contrera JF, Kruhlak NL, Matthews EJ, Benz RD. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul Toxicol Pharmacol 2007;49(3):172-182
13. Valerio LG, Yang C, Arvidson KB, Kruhlak NL. A structural feature-based computational approach for toxicology predictions. Expert Opin Drug Metab Toxicol 2010;6(4):505-518
14. Perez-Garrido A, Gonzalez MP, Escudero AG. Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity. Bioorg Med Chem 2008;16(10):5720-5732
15. Perez-Garrido A, Helguera AM, Lopez GC, et al. A topological substructural molecular design approach for predicting mutagenesis end-points of alpha, beta-unsaturated carbonyl compounds. Toxicology 2010;268(1-2):64-77
16. Nair PC, Sobhia ME. Comparative QSTR studies for predicting mutagenicity of nitro compounds. J Mol Graph Model 2008;26(6):916-934
17. Papa E, Pilutti P, Gramatica P. Prediction of PAH mutagenicity in human cells by QSAR classification. SAR QSAR Environ Res 2008;19(1-2):115-127
18. Benigni R, Bossa C. Predictivity and reliability of QSAR models: the case of mutagens and carcinogens. Toxicol Mech Methods 2008;18(2-3):137-147
19. Bentzien J, Hickey ER, Kemper RA, et al. An in silico method for predicting ames activities of primary aromatic amines by calculating the stabilities of nitrenium ions. J Chem Inf Model 2010;50(2):274-297
20. Ashby J, Tennant RW. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 1991;257(3):229-306
21. Yang C, Hasselgren CH, Boyer S, et al. Understanding genetic toxicity through data mining: the process of building knowledge by integrating multiple genetic toxicity databases. Toxicol Mech Methods 2008;18(2-3):277-295
22. Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic. Toxicol Mech Methods 2008;18(2-3):177-187
23. Benigni R, Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology. Mutat Res 2008;659(3):248-261
24. Serafimova R, Todorov M, Pavlov T, et al. Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II General Ames mutagenicity model. Chem Res Toxicol 2007;20(4):662-676
25. Ringeissen S, Note R, Dochez C, et al. Evaluation of (Q)SAR models for the prediction of mutagenicity potential. AATEX 2007;14:469-473
26. Mazzatorta P, Tran LA, Schilter B, Grigorov M. Integration of structure-activity relationship and artificial intelligence systems to improve in silico prediction of ames test mutagenicity. J Chem Inf Model 2007;47(1):34-38
27. Snyder RD. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ Mol Mutagen 2009;50(6):435-450
28. Snyder RD. Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat Res 2007;623(1-2):72-82
29. Snyder RD, Ewing D, Hendry LB. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 2006;609(1):47-59
30. Baguley BC, Wakelin LP, Jacintho JD, Kovacic P. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? Curr Med Chem 2003;10(24):2643-2649
31. Di Giorgio C, Nikoyan A, Decome L, et al. DNA-damaging activity and mutagenicity of 16 newly synthesized thiazolo[5,4-a]acridine derivatives with high photo-inducible cytotoxicity. Mutat Res 2008;650(2):104-114
32. Martin YC. What works and what does not: lessons from experience in a pharmaceutical company. QSAR and Comput Sci 2006;12:1192-1200
33. Estrada E, Molina E. Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. J Mol Graph Model 2006;25(3):275-288
34. Serra JR, Thompson ED, Jurs PC. Development of binary classification of structural chromosome aberrations for a diverse set of organic compounds from molecular structure. Chem Res Toxicol 2003;16(2):153-163
35. Williams RV, Naven RT, Marchant CA. The prediction of chromosomal effects and their mechanism of induction in Derek for Windows. International Symposium on Chromosome Aberrations (ISCA), Awaji Island, Japan, 2007, 4-6 October 2007; Available from: https://www.lhasalimited. org/resources/KL29.pdf [Last accessed 24 March 2010]
36. Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. In silico screening of chemicals for genetic toxicity using MDL-QSAR, nonparametric discriminant analysis, E-state, connectivity, and molecular property descriptors. Toxicol Mech Methods 2008;18(2-3):207-216
37. Mekenyan O, Todorov M, Serafimova R, et al. Identifying the structural requirements for chromosomal aberration by incorporating molecular flexibility and metabolic activation of chemicals. Chem Res Toxicol 2007;20(12):1927-1941
38. Olaharski AJ, Gonzaludo N, Bitter H, et al. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput Biol 2009;5(7):e1000446
39. Pearl GM, Livingston-Carr S, Durham SK. Integration of computational analysis as a sentinel tool in toxicological assessments. Curr Top Med Chem 2001;1(4):247-255
40. Snyder RD, Pearl GS, Mandakas G, et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 2004;43(3):143-158
41. Muster W, Breidenbach A, Fischer H, et al. Computational toxicology in drug development. Drug Discov Today 2008;13(7-8):303-310
42. Benigni R, Bossa C, Worth A. Structural analysis and predictive value of the rodent in vivo micronucleus assay results. Mutagenesis 2010; In press
43. Aubrecht J, Osowski JJ, Persaud P, et al. Bioluminescent Salmonella reverse mutation assay: a screen for detecting mutagenicity with high throughput attributes. Mutagenesis 2007;22(5):335-342
44. Miller JE, Vlasakova K, Glaab WE, Skopek TR. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat Res 2005;578(1-2):210-224
45. Flamand N, Meunier J, Meunier P, Agapakis-Causse C. Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. Toxicol In vitro 2001;15(2):105-114
46. Muller L, Mauthe RJ, Riley CM, et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 2006;44(3):198-211
47. Dobo KL, Greene N, Cyr MO, et al. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. Regul Toxicol Pharmacol 2006;44(3):282-293
48. Valerio LG Jr. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009;241(3):356-370
49. Kavlock RJ, Ankley G, Blancato J, et al. Computational toxicology-a state of the science mini review. Toxicol Sci 2008;103(1):14-27
50. Kavlock RJ, Austin CP, Tice RR. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 2009;29(4):485-7; discussion 92-97
51. Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv Drug Deliv Rev 2007;59(1):43-55
52. Dobo KL, Obach RS, Luffer-Atlas D, Bercu JP. A strategy for the risk assessment of human genotoxic metabolites. Chem Res Toxicol 2009;22(2):348-356
53. Ku WW, Bigger A, Brambilla G, et al. Strategy for genotoxicity testing-metabolic considerations. Mutat Res 2007;627(1):59-77